Next-generation mental health therapies.
Invest in Neuritek today!
Join us in transforming lives and pioneering the future of mental health treatment by tackling the root cause of PTSD.
We are revolutionizing mental health treatment to help patients and families suffering from psychiatric disorders.
Our vision is to reduce the risk, time and cost to bring next-generation mental health therapies to market for people suffering from psychiatric disorders, focusing initially on post-traumatic stress disorder (PTSD).
Experience and rigorous clinical science.
We are developing the first mental health treatment specifically for PTSD. This treatment will be efficient in controlling symptoms of PTSD and restoring changes in brain function which develop as a consequence of trauma exposure..
Innovative research methodologies
Neuritek is leveraging 20 years of rigorous basic and clinical research to understand how trauma affects brain and body functions. This lead to the discovery of the body’s own cannabinoid system and its relevance to PTSD.
Highly effective clinical trials.
Our clinical trial strategy utilizes a multimodality biomarker strategy, allowing designs of more targeted trials with enhanced sensitivity. We target PTSD subtypes rather than treating PTSD as a unitary disorder, leading to personalized treatments for PTSD.
